Tolerability and Effectiveness of CGB-500 Topical Ointment, 1% Tofacitinib, for the Treatment of Atopic Dermatitis

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 9, 2022

Primary Completion Date

June 30, 2023

Study Completion Date

July 30, 2023

Conditions

Atopic Dermatitis

Interventions

DRUG

Tofacitinib Citrate

Topical application of a pea-sized amount of ointment (active or vehicle) over a maximum surface of 30 cm2 up to 2 times a day.

OTHER

placebo ointment

Topical application of a pea-sized amount of ointment (active or vehicle) over a maximum surface of 30 cm2 up to 2 times a day.

Trial Locations (1)

Kani Clinic, Tbilisi